Evogene Ltd. - Ordinary Shares (EVGN): Price and Financial Metrics

Evogene Ltd. - Ordinary Shares (EVGN): $0.65

-0.03 (-4.38%)

POWR Rating

Component Grades













Add EVGN to Watchlist
Sign Up

Industry: Agriculture



in industry

EVGN Stock Summary

  • EVGN has a higher market value than just 9.99% of US stocks; more precisely, its current market capitalization is $28,232,922.
  • EVGN's price/sales ratio is 21.29; that's higher than the P/S ratio of 94.32% of US stocks.
  • With a year-over-year growth in debt of 339.3%, EVOGENE LTD's debt growth rate surpasses 95.11% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EVOGENE LTD are DARE, DRRX, SABS, PULM, and TMBR.
  • EVGN's SEC filings can be seen here. And to visit EVOGENE LTD's official web site, go to www.evogene.com.

EVGN Valuation Summary

  • EVGN's price/sales ratio is 21.2; this is 960% higher than that of the median Healthcare stock.
  • EVGN's EV/EBIT ratio has moved up 93.5 over the prior 121 months.

Below are key valuation metrics over time for EVGN.

Stock Date P/S P/B P/E EV/EBIT
EVGN 2022-11-25 21.2 0.9 -0.9 -0.3
EVGN 2022-11-23 21.3 0.9 -0.9 -0.3
EVGN 2022-11-22 20.4 0.9 -0.9 -0.3
EVGN 2022-11-21 21.1 0.9 -0.9 -0.3
EVGN 2022-11-18 22.3 1.0 -1.0 -0.4
EVGN 2022-11-17 23.0 1.0 -1.0 -0.4

EVGN Growth Metrics

    The 5 year net cashflow from operations growth rate now stands at -52.08%.
  • Its 2 year net cashflow from operations growth rate is now at -55.96%.
  • The 3 year net income to common stockholders growth rate now stands at -54.43%.
Over the past 49 months, EVGN's revenue has gone down $1,216,000.

The table below shows EVGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 1.011 -28.257 -32.077
2022-06-30 1.011 -28.257 -32.077
2022-03-31 0.834 -27.734 -29.466
2021-12-31 0.93 -24.716 -27.793
2021-12-31 0.93 -24.839 -27.793
2021-09-30 0.97 -23.505 -28.544

EVGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EVGN has a Quality Grade of D, ranking ahead of 9.47% of graded US stocks.
  • EVGN's asset turnover comes in at 0.015 -- ranking 85th of 89 Chemicals stocks.
  • 500 - Internal server error

The table below shows EVGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.015 0.448 -2.136
2019-12-31 0.012 0.556 -0.546
2018-12-31 0.026 0.169 -0.317
2017-12-31 0.039 0.159 -0.253
2016-12-31 0.063 0.138 -0.203
2015-12-31 0.093 0.258 -0.146

EVGN Price Target

For more insight on analysts targets of EVGN, see our EVGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

EVGN Stock Price Chart Interactive Chart >

Price chart for EVGN

EVGN Price/Volume Stats

Current price $0.65 52-week high $2.14
Prev. close $0.68 52-week low $0.63
Day low $0.65 Volume 51,721
Day high $0.71 Avg. volume 185,106
50-day MA $0.75 Dividend yield N/A
200-day MA $0.97 Market Cap 26.85M

Evogene Ltd. - Ordinary Shares (EVGN) Company Bio

Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company was founded in 1999 and is based in Rehovot, Israel.

EVGN Latest News Stream

Event/Time News Detail
Loading, please wait...

EVGN Latest Social Stream

Loading social stream, please wait...

View Full EVGN Social Stream

Latest EVGN News From Around the Web

Below are the latest news stories about EVOGENE LTD that investors may wish to consider to help them evaluate EVGN as an investment opportunity.

Evogene (EVGN) Reports Q3 Loss, Tops Revenue Estimates

Evogene (EVGN) delivered earnings and revenue surprises of 20% and 79.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 17, 2022

Evogene Reports Third Quarter 2022 Financial Results

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today its financial results for the third quarter, ended September 30, 2022.

Yahoo | November 17, 2022

Casterra Signs Royalty Agreement with Titan for Castor Oil Sales in South-Eastern Africa

Casterra Ag Ltd. ("Casterra"), the castor seeds technology developer whose mission is to provide the most advanced castor bean seed varieties and comprehensive ag-service solutions to castor cultivators and manufacturers, and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) ("Evogene"), announced today that it signed a long-term royalty agreement with Titan Castor Farms Limited ("Titan"), a Zambian cultivator, manufacturer and distributor of castor oil.

Yahoo | November 15, 2022

Biomica CEO to Participate in an Industry Panel Discussion at Microbiome Connect USA 2022 Summit

Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be participating in an Industry panel discussion at the 7th Annual Microbiome Connect USA 2022 Summit taking place between November 16-17, 2022, in Boston, MA.

Yahoo | November 14, 2022

Evogene Schedules Third Quarter of 2022 Financial Results Release & Conference Call for November 17, 2022

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development announced today that it will release its financial results for the third quarter of 2022 on Thursday, November 17, 2022.

Yahoo | November 7, 2022

Read More 'EVGN' Stories Here

EVGN Price Returns

1-mo -17.58%
3-mo -45.83%
6-mo -28.58%
1-year -67.98%
3-year -52.21%
5-year -83.03%
YTD -60.37%
2021 -65.11%
2020 209.21%
2019 -23.23%
2018 -35.50%
2017 -39.80%

Continue Researching EVGN

Want to see what other sources are saying about Evogene Ltd's financials and stock price? Try the links below:

Evogene Ltd (EVGN) Stock Price | Nasdaq
Evogene Ltd (EVGN) Stock Quote, History and News - Yahoo Finance
Evogene Ltd (EVGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9444 seconds.